

Web conference - Q4 sales

January 16, 2025

Participants from Oncopeptides

- Sofia Heigis, CEO
- Henrik Bergentoft, CFO




What have we announced?


- Q4 sales figure (18.6 mSEK).
- Updated cash-flow expectations (2027).
- Progress in Japan discussions.
- Sharpened focus in Germany.
- Glioblastoma an emerging opportunity.



Where we are right now




Our potential




A global biotech with a marketed product, expanding indications, and a proprietary platform unlocking future therapies

Drivers of European growth



Revenue, European sales, million SEK



A woman with dark hair pulled back, wearing glasses and a light blue t-shirt, is shown from the chest up, smiling and looking to her right. She is seated in a wheelchair, with the black handle of the chair visible. The image is framed by a large, semi-transparent circular graphic that is split vertically, with the left side being a lighter shade of gray and the right side being a darker shade. The background is a plain, light-colored wall.

**European
commercialization**




Our ambition:


launch as fast as possible with a price reflecting our innovation - providing patient and shareholder value.

Europe

Q4 2024




Q4 2025




Spain

Q4 2024




Q4 2025



Germany

Q4 2024



Q4 2025



Italy


Q4 2024




Q4 2025



European commercialization



Market exclusivity until 2037




% of market potential per phase out of SEK ≈1.5 billion estimated annual market potential.





Partnerships

Pepaxti commercialization and partnership landscape



Oncopeptides' expansion strategy can be summarized as: **grow geographically, partner smartly, and innovate purposefully.**

Japan partnership potential

**Growing
patient
population**

**Fast market
access**

**Comparable to
German market
potential**

**Favorable
regulatory
landscape**

**High unmet
need in 4L+
setting**

A close-up portrait of a woman with a stethoscope around her neck, looking slightly to the side. The image is overlaid with a large, semi-transparent blue circle on the left side. Inside this circle, the text "Beyond Multiple Myeloma" is written in white, bold, sans-serif font. The background is a soft, out-of-focus light green and yellow.

Beyond Multiple Myeloma



Glioblastoma

Glioblastoma: brain tumor with high unmet need & growing market potential

Most aggressive brain cancer – grows fast, invariably relapses, and has no cure.


Rare but severe – affects about 2-3 people per 100,000 each year, usually above the age of 60.

Poor survival – even with treatment, patients live only about 12-15 months after diagnosis.

New, brain-penetrating therapies are urgently needed.



Glioblastoma



Blood brain barrier


PDCs have potential to help patients with brain tumors, such as glioblastoma

Critical BBB passage confirmed

- OPD5 has shown promising preclinical data
- OPD5 has shown an efficient blood-brain barrier penetration and strong tumor reduction in preclinical models

Reminder:

The mode of action of PDCs enhances alkylation by linking a peptide carrier to a cytotoxic payload, resulting in a lipophilic compound




1. Wickstrom M, et al. Oncotarget. 2017;8(25):44441-44455. 2. Wickstrom M, et al. Biochem Pharmacol. 2015;79(5):1281-1290.
3. Cheah D, et al. Clin Cancer Res. 2013;19(11):3019-3031. 4. Ray A, et al. Br J Haematol. 2016;176(3):397-409.

oncopeptides

Glioblastoma market potential

- Global Market Value 2024
- Global Market Value 2035



Fast-to-market opportunity

- High unmet medical need and very modest efficacy of existing therapies
- High probability of an accelerated approval based on single-arm Ph1/2 data in relapsed glioblastoma

Summary: OPD5 in glioblastoma

Very high **unmet need** and **market potential**

Strong **therapeutic rationale** and **differentiated mode of action**

Potential for **accelerated approval**



In closing

Reasons to believe

Europe

SEK \approx 1.5 billion/year
market potential

RoW

Opportunities outside
of key markets remain
strong

Pipeline

Strengthened
opportunity in
pipeline value drivers



Q&A



**Bringing hope
through science**

